A Metastatic Neuroblastic Tumor in a 28-Month-old Boy: Unusual Spontaneous Regression From Neuroblastoma to Ganglioneuroma?
Journal
Journal of pediatric hematology/oncology
ISSN: 1536-3678
Titre abrégé: J Pediatr Hematol Oncol
Pays: United States
ID NLM: 9505928
Informations de publication
Date de publication:
01 Mar 2022
01 Mar 2022
Historique:
received:
20
01
2021
accepted:
05
05
2021
pubmed:
1
6
2021
medline:
20
4
2022
entrez:
31
5
2021
Statut:
ppublish
Résumé
Neuroblastoma with bone metastasis is well known to have an extremely poor prognosis. We experienced the case of a patient with adrenal ganglioneuroblastoma (GNB) with metastases of subcutaneous nodules, a lymph node, and multiple bones. A pathologic examination of tumors from different sites revealed both GNB and ganglioneuroma. A genetic comparison between these tumors identified the same molecular signatures, suggesting the possibility of spontaneous differentiation in the remaining GNB. The patient has been healthy without aggressive chemotherapy, and the patient's pathologic urinary catecholamines normalized. Even if unusual, we have to recognize probable spontaneous differentiation from neuroblastoma to GNB and then to ganglioneuroma, even in sites of bone metastasis.
Identifiants
pubmed: 34054050
doi: 10.1097/MPH.0000000000002226
pii: 00043426-202203000-00077
doi:
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e589-e592Informations de copyright
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Maris JM. Recent advances in neuroblastoma. N Engl J Med. 2010;362:2202–2211.
George RE, Li S, Medeiros-Nancarrow C, et al. High-risk neuroblastoma treated with tandem autologous peripheral-blood stem cell-supported transplantation: long-term survival update. J Clin Oncol. 2006;24:2891–2896.
Drago G, Pasquier B, Pasquier D, et al. Malignant peripheral nerve sheath tumor arising in a “de novo” ganglioneuroma: a case report and review of the literature. Med Pediatr Oncol. 1997;28:216–222.
Iehara T, Yoneda A, Yokota I, et al. Results of a prospective clinical trial JN-L-10 using image-defined risk factors to inform surgical decisions for children with low-risk neuroblastoma disease: a report from the Japan Children’s Cancer Group Neuroblastoma Committee. Pediatr Blood Cancer. 2019;66:e27914.
Nickerson HJ, Matthay KK, Seeger RC, et al. Favorable biology and outcome of stage IV-S neuroblastoma with supportive care or minimal therapy: a Children’s Cancer Group study. J Clin Oncol. 2000;18:477–486.
Van Noesel MM, Hählen K, Hakvoort-Cammel FG, et al. Neuroblastoma 4S: a heterogeneous disease with variable risk factors and treatment strategies. Cancer. 1997;80:834–843.
Brodeur GM. Spontaneous regression of neuroblastoma. Cell Tissue Res. 2018;372:277–286.
Garvin JH, Lack EE, Berenberg W, et al. Ganglioneuroma presenting with differentiated skeletal metastases. Report of a case. Cancer. 1984;54:357–360.
Dai X, Zhang R, Li Y, et al. Multiple ganglioneuromas: a report of a case and review of the ganglioneuromas. Clin Neuropathol. 2009;28:193–196.
Wei JS, Greer BT, Westermann F, et al. Prediction of clinical outcome using gene expression profiling and artificial neural networks for patients with neuroblastoma. Cancer Res. 2004;64:6883–6891.
Ohira M, Oba S, Nakamura Y, et al. Expression profiling using a tumor specific cDNA microarray predicts the prognosis of intermediate risk neuroblastomas. Cancer Cell. 2005;7:337–350.
Tomioka N, Oba S, Ohira M, et al. Novel risk stratification of patients with neuroblastoma by genomic signature, which in independent of molecular signature. Oncogene. 2008;27:441–449.